Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 6/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12709179 | 0.83 | THRB (0.43) | ALDH1A1TDP1ACHETSHRMEN1 | |
| SCHEMBL4947151 | 0.80 | ACHE (0.53) | EPHX1ACHETSHR | |
| SCHEMBL15998711 | 0.79 | TSHR (0.40) | ALDH1A1TSHR | |
| SCHEMBL4198420 | 0.76 | ALDH1A1 (0.55) | ALDH1A1TDP1TSHRKMT2A | |
| SCHEMBL4946707 | 0.76 | ALDH1A1 (0.43) | EPHX1ALDH1A1ACHETSHRMEN1 | |
| SCHEMBL19884887 | 0.75 | ACHE (0.56) | EPHX1ACHETSHR | |
| SCHEMBL275242 | 0.75 | ACHE (0.56) | EPHX1ACHETSHR | |
| SCHEMBL11510191 | 0.74 | ACHE (0.56) | ACHETSHR | |
| SCHEMBL14368854 | 0.74 | ACHE (0.56) | ACHETSHR | |
| SCHEMBL13872032 | 0.73 | ACHE (0.58) | ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076441-B2 | Process for bridging organically polymerizable silanes or silane resin systems containing hydroxy- or carboxylic acid groups as well as products obtained with said process | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20080319127-A1 | Method for Bridging Organically Polymerisable Silanes or Silane Resin Units Containing Hydroxy Groups or Carboxylic Acid Groups, and Products of Said Method | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319127-A1 | Method for Bridging Organically Polymerisable Silanes or Silane Resin Units Containing Hydroxy Groups or Carboxylic Acid Groups, and Products of Said Method | PCNA, POLR1G, POLR1A | EPHX1 760/4885KDM4E 2186/4885MAPK1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.